[ad_1]
UAE: AstraZeneca, a global, science-led biopharmaceutical company, announces the launch of its revolutionary cancer drug IMJUDO® (tramelimumab) in the UAE, becoming the first country in the Middle East to receive the drug One, marking a major advance in cancer treatment.
Clinical trials have demonstrated the efficacy and tolerability of IMJUDO® combination therapy in various types of cancer, including metastatic non-small cell lung cancer and hepatobiliary cancer. The drug has shown promising results in prolonging progression-free survival and overall survival, enabling patients to achieve better treatment outcomes and a higher quality of life.
AstraZeneca has organized a series of seminars and conferences to introduce new medicines to healthcare experts in the UAE. More than 100 healthcare professionals from major cancer care institutions attended. During the conference, several regional and international healthcare experts presented revolutionary data and identified unmet needs using immunotherapy combinations to improve survival for patients with liver and lung cancer who desperately need new effective drugs.
The launch of IMJUDO® in the UAE is in line with its growing focus on quality cancer care, with more than 30 cancer centers and clinics across the country.[i] Following the directives of the Ministry of Health and Prevention (MoHAP), the UAE has been implementing a comprehensive strategy to enhance cancer care, improve early detection and promote innovative treatments. The launch of IMJUDO® reinforces the UAE’s commitment to advancing oncology care and providing patients and families with access to cutting-edge therapies.
Additionally, the launch of innovative medicines reflects AstraZeneca’s commitment to changing the landscape of comprehensive cancer care in the UAE and Middle East. The company is committed to improving patient outcomes and family well-being, and IMJUDO® is a testament to this mission.
On the occasion, Sameh El Fangary, President, GCC and AstraZeneca Pakistan Cluster, said: “Our mission is to continue working with our partners to transform health and well-being for people, societies and planet. This collaboration underscores our Unwavering Commitment: Inspired by our strategic focus on eliminating cancer-related deaths, accelerating the latest innovations in the UAE and the region. We are proud of our successful presence in the UAE for over 40 years and our ongoing partnership with MOHAP, which enables Together we are able to bring the latest and most innovative healthcare solutions to the UAE.”
Dr Humaid Al Shamsi, President of the Emirates Oncology Society, added: “IMJUDO® represents a significant step forward in our global fight against multiple cancers, especially with major data supporting this revolutionary drug showing that it is the first and only An approved therapy in combination with IMFINZI® has 3 years of data in first-line advanced or unresectable hepatocellular carcinoma. This breakthrough immunotherapy drug offers new hope for patients and their families. It also Strengthens the UAE’s position as a leader in cancer care in the Middle East and a global healthcare destination. We look forward to seeing the positive impact of IMJUDO® on patient outcomes and continuing our partnership with AstraZeneca in the fight against cancer.”
AstraZeneca remains committed to ensuring the availability and accessibility of IMJUDO® in the UAE as the company continues to work with healthcare providers, policy makers and patient advocacy groups to raise awareness of IMJUDO® and its transformational Awareness of role in cancer treatment.
-over-
Linzhu Hall
IMJUDO® (Tremelimumab) is a human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). IMJUDO® blocks the activity of CTLA-4, promotes T cell activation, triggers an immune response against cancer and promotes cancer cell death
summarize
IMFINZI® (durvalumab) is a humanized monoclonal antibody that binds to PD-L1 protein and blocks the interaction of PD-L1 with PD-1 and CD80 proteins, counteracts tumor immune evasion strategies and releases anti-tumor inhibition.
AstraZeneca is leading an oncology revolution with the ambition to provide treatments for all forms of cancer, following science to understand cancer and all its complexities, to discover, develop and deliver life-changing medicines to patients.
The company’s focus is on some of the most challenging cancers. It is through relentless innovation that AstraZeneca has built one of the most diverse product portfolios and product lines in the industry, with the potential to revolutionize the practice of medicine and transform the patient experience.
AstraZeneca’s vision is to redefine cancer treatment and one day eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines in oncology, rare diseases and biopharmaceuticals, including cardiovascular , Kidneys & Metabolism, and Respiratory & Immunology. Headquartered in Cambridge, UK, AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients around the world.please visit AstraZeneca and follow the company on Twitter @AstraZeneca.
[ad_2]
Source link